Evaluation of Real-Life Investigational Use of Enoximone in Asthma, the Third Step in Drug Repurposing: A Preliminary Report

Figure 1

Asthma patients were able to phase down asthma medication when enoximone was taken (ICS use reduction according to GINA guidelines). Asthma patients were treated at least 3 months with enoximone (n = 41; enoximone 15–105 mg/week (in 1–7 dosages)). (a) Asthmatic patients (n = 41) using or having used enoximone (on enox./after). (b) No traditional asthma medication was needed any more (n = 9). (c) Only enoximonetherapy with incidental SABA/LABA (n = 21). (d) Enoximone together with ICS (n = 11) (Wilcoxon matched-pairs signed rank test  = ;  = ;  = ) (enox. = enoximone).

(a)

(b)

(c)

(d)